Submission to TGA consultation on medicine labelling

Our submission to a Therapeutic Goods Administration (TGA) consultation, backs proposed replacement standards for TGO 91 and TGO 92, provided the changes strengthen safety and reduce avoidable medication errors.  

The submission advocates for labels that make it easy for people to identify the medicine they are taking. It supports the active ingredient (generic) name being the primary information on the label, with brand names secondary. This is a practical fix that reduces confusion when brands change due to substitution, supporting safer care.